Phreesia, Inc. (NYSE:PHR) Given Consensus Recommendation of “Buy” by Brokerages

by · The Markets Daily

Phreesia, Inc. (NYSE:PHR – Get Free Report) has earned an average rating of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $32.5833.

Several equities analysts have commented on the company. Truist Financial upped their price target on Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, May 29th. KeyCorp upped their price target on Phreesia from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 14th. Wall Street Zen raised Phreesia from a “hold” rating to a “buy” rating in a report on Sunday, June 1st. Canaccord Genuity Group cut their price target on Phreesia from $35.00 to $34.00 and set a “buy” rating for the company in a report on Thursday, May 29th. Finally, Mizuho initiated coverage on Phreesia in a report on Wednesday, August 27th. They issued an “outperform” rating and a $36.00 target price for the company.

Check Out Our Latest Stock Analysis on PHR

Phreesia Trading Down 0.6%

Phreesia stock opened at $31.47 on Friday. The business has a 50 day moving average price of $28.22 and a two-hundred day moving average price of $26.52. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -42.52 and a beta of 0.72. Phreesia has a 12 month low of $17.07 and a 12 month high of $32.76.

Insiders Place Their Bets

In other news, insider Evan Roberts sold 45,147 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $32.02, for a total value of $1,445,606.94. Following the completion of the transaction, the insider directly owned 727,768 shares of the company’s stock, valued at approximately $23,303,131.36. This represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David Linetsky sold 23,729 shares of the stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $28.50, for a total value of $676,276.50. Following the completion of the transaction, the senior vice president directly owned 193,510 shares of the company’s stock, valued at approximately $5,515,035. The trade was a 10.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 119,874 shares of company stock worth $3,587,618 in the last 90 days. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Phreesia

Hedge funds have recently modified their holdings of the stock. Quarry LP raised its holdings in shares of Phreesia by 210.9% in the 4th quarter. Quarry LP now owns 2,835 shares of the company’s stock worth $71,000 after buying an additional 1,923 shares in the last quarter. KBC Group NV acquired a new position in shares of Phreesia in the 1st quarter worth approximately $74,000. Farther Finance Advisors LLC raised its holdings in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock worth $86,000 after buying an additional 3,000 shares in the last quarter. CWM LLC grew its position in Phreesia by 994.9% during the 1st quarter. CWM LLC now owns 4,040 shares of the company’s stock worth $103,000 after acquiring an additional 3,671 shares during the last quarter. Finally, NewEdge Advisors LLC grew its position in Phreesia by 12.1% during the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock worth $107,000 after acquiring an additional 459 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Featured Articles